
argenx (ARGX) Stock Forecast & Price Target
argenx (ARGX) Analyst Ratings
Bulls say
Argenx has achieved breakeven on operating profit in the third quarter of 2024, with expectations for improving operating margins driven by increased sales and stabilized R&D spending. The company reported impressive growth with $737 million in global product net sales for the fourth quarter of 2024, reflecting a 29% quarter-over-quarter and 97% year-over-year increase, marking the 12th consecutive quarter of revenue growth fueled by its lead product, Vyvgart, and the newly approved formulation for Chronic Inflammatory Demyelinating Polyneuropathy. Argenx's commitment to innovation is evidenced by its robust pipeline and R&D investment strategy, which aims to sustain momentum and capitalize on the potential for future growth within the biopharmaceutical market.
Bears say
Argenx has reported a slight decline in R&D expenses, which fell 3.0% year-over-year to $297.2 million in 4Q23, indicating potential concerns regarding the sustainability of investment in key programs amidst financial uncertainties. The company faces multiple risks, including lower-than-expected growth in Vyvgart sales, potential safety concerns from ongoing trials, and increased competition, which could jeopardize its future revenue streams and hinder pipeline advancements. Furthermore, the financial outlook is further clouded by the ongoing challenges seen in the biopharmaceutical sector, exemplified by competitors experiencing revenue stagnation due to factors such as loss of exclusivity and difficulties in transitioning patients to new therapies.
This aggregate rating is based on analysts' research of argenx and is not a guaranteed prediction by Public.com or investment advice.
argenx (ARGX) Analyst Forecast & Price Prediction
Start investing in argenx (ARGX)
Order type
Buy in
Order amount
Est. shares
0 shares